Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | active not recruiting | Phase 3 | 747 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 5, 2026 | clinicaltrials |
| NCT04620603 | Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer | active not recruiting | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05946993 | Linking In With Advice and Supports for Men Impacted by Metastatic Cancer(LIAM Mc) | active not recruiting | N/A | 72 | University College CorkOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT03354390 | HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 1 | 17 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Apr 28, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01590069 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | active not recruiting | Phase 1 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04393350 | Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma | active not recruiting | Phase 2 | 18 | Emory UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT00918775 | Follow-up After Metastasectomy in Patients With Kidney Cancer | active not recruiting | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04953104 | ARID1A and/or KDM6A Mutation and CXCL13 Expression | active not recruiting | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05347212 | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | active not recruiting | Phase 2 | 50 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 37 | Hao ZengOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02664883 | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | active not recruiting | — | 37 | University of Southern CaliforniaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT07492225 | Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial | active not recruiting | Phase 2 | 120 | Changhai HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07488533 | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06126159 | MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers | active not recruiting | N/A | 44 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03185039 | Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03996850 | SPECT/CT for the Characterization of Renal Masses | active not recruiting | — | 102 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06964958 | 177LuPSMA in Renal Cell Carcinoma(LASER) | active not recruiting | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma(CLEAR) | active not recruiting | Phase 3 | 1,069 | Eisai Inc.INDUSTRY | 20 | Feb 23, 2026 | clinicaltrials |
| NCT04258462 | Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors | active not recruiting | Phase 2 | 54 | Zhen Wang, MDOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma | active not recruiting | Phase 2 | 6 | Emory UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02950766 | NeoVax Plus Ipilimumab in Renal Cell Carcinoma | active not recruiting | Phase 1 | 19 | Patrick Ott, MD, PhDOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04645680 | Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy(DIET) | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT02473536 | Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC | active not recruiting | Phase 1 / Phase 2 | 25 | University of Texas Southwestern Medical CenterOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05239533 | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07332923 | Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning | active not recruiting | — | 500 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT02399124 | Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma(ICE-SECRET) | active not recruiting | N/A | 120 | IceCure Medical Ltd.INDUSTRY | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT02141919 | Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer | active not recruiting | Phase 2 | 16 | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05030506 | A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | active not recruiting | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06846112 | Randomized Clinical Trial Aimed at Comparing Unclamped Robotic Partial Nephrectomy With or Without Renorrhaphy | active not recruiting | N/A | 248 | Regina Elena Cancer InstituteOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05363631 | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Mohammed MilhemOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05696444 | Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO) | active not recruiting | N/A | 144 | Medtronic - MITGINDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 5, 2026source: clinicaltrials